Pharma major Wockhardt today said it has received approval from the US drug regulator for marketing its anti-epileptic tablet Levetiracentam in that country.
The company has received approval from the United States Food & Drug Administration (USFDA) for marketing of Levetiracentam tablets in the strength of 250, 500, 750 mg and 1 gm, Wockhardt said in a filing to the Bombay Stock Exchange.
Levetiracentam tablets are used in the treatment of various kinds of epileptic seizures.
"With nearly 60 products now in the market, we are continuing to strengthen our US business by filing several abbreviated new drug approvals all indigenously developed by the company's research and development team," Wockhardt Chairman Habil Khorakiwala said.
On Wednesday, Wockhardt had said the company has received final approval from the USFDA for the marketing of Divalporex Extended Release (ER) tablets also used in the treatment of various kinds of epileptic seizures.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app